First Ebola Case in U.S. Keeps the Ebola Trade Rolling
Insights - Just after the close on Tuesday the United States’ Centers for Disease Control and Prevention (CDC) confirmed the first infection of Ebola Zaire in a … Continue Reading
Read NowInsights
J&J Puts Up $2 Billion for Viral Therapeutics, Spotlights Two Other Public Companies
Insights - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset is compound … Continue Reading
Read Now
Firdapse, Catalyst Pharma Produce Phase 3 Success
Insights - Catalyst Pharmaceuticals’ (CPRX) Firdapse (amifampridine phosphate) hit both co-primary endpoints successfully in a phase 3 trial in Lamberton-Eaton myasthenic syndroms (LEMS), announced on Monday afternoon. The stock climbed 20% … Continue Reading
Read Now
Latest Must-Knows for Arrowhead Research
Insights - Arrowhead Research (ARWR) presented on Friday at Biocentury’s Newsmakers in the Biotech Industry conference. Investors are paying close attention given an important data event in November for ARC-520 … Continue Reading
Read Now
Cempra’s Phase 3 Trial Enrolled Faster than Expected
Insights - Cempra, Inc. (CEMP) enrolled patients in SOLITAIRE-Oral, a phase 3 trial of lead antibiotic solithromycin, slightly faster than expected, announcing completion on Thursday that puts a … Continue Reading
Read Now
Over-Optimism Comes Back to Bite AcelRx Following FDA Meeting
Insights - Following a teleconference with the FDA, AcelRx Pharmaceuticals (ACRX) says that a resubmission of the Zalviso New Drug Application won’t occur until the first quarter … Continue Reading
Read Now
Acorda Puts Cash Trove to Use, Cynapsus Feels the Effects
Insights - Acorda Therapeutics (NASDAQ:ACOR) will acquire privately-held Civitas Therapeutics for $525 million in cash, adding the phase 3-ready treatment for OFF episodes in Parkinson’s Disease (PD), CVT-301, to its roster … Continue Reading
Read Now